Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease
Caroline Benn, Lee A. Dawson
Frontiers in Aging Neuroscience (2020) Vol. 12
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Enhancing autophagy in Alzheimer's disease through drug repositioning
Mehdi Eshraghi, Mazaher Ahmadi, Saeid Afshar, et al.
Pharmacology & Therapeutics (2022) Vol. 237, pp. 108171-108171
Closed Access | Times Cited: 68
Kinase-Modulated Bioluminescent Indicators Enable Noninvasive Imaging of Drug Activity in the Brain
Yan Wu, Joel R. Walker, Michael Westberg, et al.
ACS Central Science (2023) Vol. 9, Iss. 4, pp. 719-732
Open Access | Times Cited: 19
An Update on Protein Kinases as Therapeutic Targets—Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases
Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17600-17600
Open Access | Times Cited: 17
Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases
Caroline Benn, Karl R. Gibson, David S. Reynolds
Journal of Huntington s Disease (2020) Vol. 10, Iss. 1, pp. 203-220
Open Access | Times Cited: 33
Kinetic and thermodynamic study of ALP enzyme in the presence and absence MWCNTs and Pt-NPs nanocomposites
Mohammed Faiad Naief, Ahmed Mishaal Mohammed, Yousif H. Khalaf
Results in Chemistry (2023) Vol. 5, pp. 100844-100844
Open Access | Times Cited: 12
Recent advances in PKC inhibitor development: Structural design strategies and therapeutic applications
Wen Li, Kun Zhu, Yuyin Liu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117290-117290
Closed Access
New Serious Safety Warnings for Targeted Anticancer Agents After Their Initial FDA Approval
Dimitar Stefanovski, Damjan Manevski, Domen Ribnikar, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 584-584
Open Access
Unlocking the therapeutic potential of protein kinase inhibitors in neurodegenerative and psychiatric disorders
A. V., Polina Buzaeva, Izhak Michaelevski
(2025) Vol. 2, Iss. 6
Open Access
Going beyond ATP binding site as a novel inhibitor design strategy for tau protein kinases in the treatment of alzheimer's disease: A review
Marwa A. Zaater, Ahmed M. El Kerdawy, Walaa R. Mahmoud, et al.
International Journal of Biological Macromolecules (2025), pp. 142141-142141
Closed Access
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
Sandeep Rana, Jayapal Reddy Mallareddy, Sarbjit Singh, et al.
Cancers (2021) Vol. 13, Iss. 21, pp. 5506-5506
Open Access | Times Cited: 24
Kinetic evaluation and study of gold-based nanoparticles and multi-walled carbon nanotubes as an alkaline phosphatase inhibitor in serum and pure form
Samar Naser Mohammed, Khalid F. Al-Rawi, Ahmed Mishaal Mohammed
Carbon letters (2023) Vol. 33, Iss. 4, pp. 1217-1229
Closed Access | Times Cited: 10
Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease
Laura Martínez-Drudis, Razan Sheta, Rémi Pellegrinato, et al.
Neurobiology of Disease (2022) Vol. 172, pp. 105833-105833
Closed Access | Times Cited: 10
Structural Insights and Development of LRRK2 Inhibitors for Parkinson’s Disease in the Last Decade
Gunjan Thakur, Vikas Kumar, Keun Woo Lee, et al.
Genes (2022) Vol. 13, Iss. 8, pp. 1426-1426
Open Access | Times Cited: 10
CK2 and protein kinases of the CK1 superfamily as targets for neurodegenerative disorders
Andrea Baier, Ryszard Szyszka
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 9
The emerging role of mixed lineage kinase 3 (MLK3) and its potential as a target for neurodegenerative diseases therapies
Ricardo Alberto Moreno, Javier Bueno, Santiago Barber, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115511-115511
Open Access | Times Cited: 4
An Update on Protein Kinases as Therapeutic Targets—Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein–Protein Interactions
Mulate Zerihun, Samuel J. S. Rubin, Shmuel Silnitsky, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17504-17504
Open Access | Times Cited: 4
Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation
Vanesa Nozal, Paula Fernández-Gómez, Alfonso García‐Rubia, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116626-116626
Open Access | Times Cited: 1
Drug repurposing using meta-analysis of gene expression in Alzheimer’s disease
Ha Young Jang, Jung Mi Oh, In‐Wha Kim
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 6
Single‐Molecule Enzymology for Diagnostics: Profiling Alkaline Phosphatase Activity in Clinical Samples
Tal Gilboa, Alana F. Ogata, David R. Walt
ChemBioChem (2021) Vol. 23, Iss. 1
Closed Access | Times Cited: 7
Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces—A Review
Zoltán Köllő, Miklós Garami, István Vincze, et al.
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 239-239
Open Access | Times Cited: 2
Reversing memory/cognitive impairment with medicinal plants targeting inflammation and its crosstalk with other pathologies
Sheena E.B. Tyler, Luke D.K. Tyler
Brain Disorders (2023) Vol. 11, pp. 100094-100094
Open Access | Times Cited: 2
A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood–brain barrier
Paul W. Manley, Felix Huth, Saliha Moussaoui, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 59, pp. 128577-128577
Closed Access | Times Cited: 4
Assessing the Inhibitory Potential of Kinase Inhibitors In Vitro: Major Pitfalls and Suggestions for Improving Comparability of Data Using CK1 Inhibitors as an Example
Aileen Roth, Adrian Gihring, Florian Göser, et al.
Molecules (2021) Vol. 26, Iss. 16, pp. 4898-4898
Open Access | Times Cited: 5
RPS6 transcriptional modulation in neural tissues of Nauphoeta cinerea during streptozotocin-associated sugar metabolism impairment.
Olawande C. Olagoke, Ana Lúcia Anversa Segatto, Blessing A. Afolabi, et al.
Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology (2022) Vol. 263, pp. 110785-110785
Closed Access | Times Cited: 3
Protein Kinase Inhibitors - Selectivity or Toxicity?
Moran Grossman, Elaine Adler
Biochemistry (2021)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top